Intellia Therapeutics (NTLA) Stock Price, News & Analysis

Company Overview

Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach. The company maintains a collaboration and license agreement with Regeneron Pharmaceuticals to advance in vivo therapies for ophthalmic and other systemic diseases. In the ex vivo space, Intellia has entered into an alliance with Novartis to harness CRISPR/Cas9 for engineering allogeneic CAR-T cells for cancer immunotherapy, with the goal of producing “off‐the‐shelf” cell therapies.

Founded in 2014 as a spin-out from Caribou Biosciences, Intellia went public in 2016 and is headquartered in Cambridge, Massachusetts, with research operations in the San Francisco Bay Area and an innovation center in the United Kingdom. The company’s leadership team is led by President and Chief Executive Officer John Leonard, M.D., who brings extensive experience in oncology and cell therapy development, supported by a seasoned executive cadre in R&D, manufacturing and regulatory affairs.

Intellia serves a global patient population through its proprietary platform and collaborative network, with a focus on creating one‐time treatments that have the potential to transform the standard of care for patients with debilitating genetic diseases. The company continues to advance multiple programs through clinical and preclinical milestones toward regulatory filings and broader commercialization.

Key Stats

• Today's Range: $11.63 to $12.24
• 50-Day Range: $9.38 to $14.24
• 52-Week Range: $5.90 to $23.76
• Volume: 5.16 million shs
• Average Volume: 4.04 million shs
• Market Capitalization: $1.29 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $29.05
• Consensus Rating: Moderate Buy

Intellia Therapeutics Stock Analysis - MarketRank™

Intellia Therapeutics scored higher than 94% of companies evaluated by MarketBeat, and ranked 73rd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Intellia Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.58, and is based on 12 buy ratings, 6 hold ratings, and 1 sell rating.

Upside Potential

Intellia Therapeutics has a consensus price target of $29.05, representing about 140.9% upside from its current price of $12.06.

Amount of Analyst Coverage

Intellia Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Intellia Therapeutics are expected to grow in the coming year, from ($5.07) to ($5.00) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Intellia Therapeutics is -2.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Intellia Therapeutics is -2.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Intellia Therapeutics has a P/B Ratio of 1.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

25.83% of the outstanding shares of Intellia Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Intellia Therapeutics has a short interest ratio ("days to cover") of 5.4.

Change versus previous month

Short interest in Intellia Therapeutics has recently decreased by 6.66%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Intellia Therapeutics does not currently pay a dividend.

Dividend Growth

Intellia Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.67

Percentage of Shares Shorted

25.83% of the outstanding shares of Intellia Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Intellia Therapeutics has a short interest ratio ("days to cover") of 5.4.

Change versus previous month

Short interest in Intellia Therapeutics has recently decreased by 6.66%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.38

News Sentiment

Intellia Therapeutics has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Intellia Therapeutics this week, compared to 13 articles on an average week.

Search Interest

Only 28 people have searched for NTLA on MarketBeat in the last 30 days. This is a decrease of -48% compared to the previous 30 days.

MarketBeat Follows

13 people have added Intellia Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 8% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Intellia Therapeutics insiders have bought 551.99% more of their company's stock than they have sold. Specifically, they have bought $1,003,000.00 in company stock and sold $153,837.00 in company stock.

Percentage Held by Insiders

Only 3.10% of the stock of Intellia Therapeutics is held by insiders.

Percentage Held by Institutions

88.77% of the stock of Intellia Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NTLA Stock Analysis - Frequently Asked Questions

How have NTLA shares performed this year?

Intellia Therapeutics' stock was trading at $11.66 at the beginning of the year. Since then, NTLA shares have increased by 3.4% and is now trading at $12.06.

How were Intellia Therapeutics' earnings last quarter?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) released its earnings results on Thursday, August, 7th. The company reported ($0.99) earnings per share for the quarter, topping the consensus estimate of ($1.03) by $0.04. Intellia Therapeutics's quarterly revenue was up 104.3% compared to the same quarter last year.
Read the conference call transcript.

When did Intellia Therapeutics IPO?

Intellia Therapeutics (NTLA) raised $85 million in an initial public offering on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Intellia Therapeutics' major shareholders?

Top institutional shareholders of Intellia Therapeutics include ARK Investment Management LLC (12.57%), Sumitomo Mitsui Trust Group Inc. (2.58%), Nikko Asset Management Americas Inc. (2.49%) and Geode Capital Management LLC (2.52%). Insiders that own company stock include John M Leonard, William J Chase, Eliana Clark, James Basta, Michael P Dube, David Lebwohl, Laura Sepp-Lorenzino, Glenn Goddard and Jesse Goodman.
View institutional ownership trends.

How do I buy shares of Intellia Therapeutics?

Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Intellia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Intellia Therapeutics investors own include Chevron (CVX), Bristol Myers Squibb (BMY), Comcast (CMCSA), NVIDIA (NVDA), Charles Schwab (SCHW), Meta Platforms (META) and Edwards Lifesciences (EW).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/06/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NTLA
• CIK: 1652130
• Web: www.intelliatx.com
• Phone: (857) 285-6200
• Fax: N/A
• Employees: 600
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Intellia Therapeutics: $29.05
• High Price Target: $64.00
• Low Price Target: $7.00
• Potential Upside/Downside: +140.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.58
• Research Coverage: 19 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$519.02 million
• Net Margins: -908.48%
• Pretax Margin: -908.48%
• Return on Equity: -57.48%
• Return on Assets: -45.04%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.19
• Quick Ratio: 5.19

Sales & Book Value

• Annual Sales: $57.88 million
• Price / Sales: 22.37
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.56 per share
• Price / Book: 1.41

Miscellaneous

• Outstanding Shares: 107,350,000
• Free Float: 104,019,000
• Market Cap: $1.29 billion
• Optionable: Optionable
• Beta: 2.28